SCHEMBL39912

SCHEMBL39912

CC(C)(C)OC(=O)NCCCCC(=O)c1ccco1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
ALDH1A1 P00352 3/20 0.50
PKM P14618 1/20 0.50
MAPT P10636 3/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
NPSR1 Q6W5P4 1/20 0.46
SIGMAR1 Q99720 2/20 0.45
ADORA2A P29274 2/20 0.45
ADORA1 P30542 2/20 0.45
IDO1 P14902 1/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
ADORA2B P29275 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24831487 0.91 SMN1; SMN2 (0.54) CYP3A4SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL3724183 0.79 ALDH1A1 (0.59) SMN1; SMN2NPC1RAB9AALDH1A1PKM
SCHEMBL10322699 0.79 L3MBTL1 (0.53) CYP3A4MAPTKMT2AMEN1TDP1
SCHEMBL24831465 0.77 CTSS (0.50) SMN1; SMN2NPC1RAB9AMAPTKMT2A
SCHEMBL3939808 0.77 SMN1; SMN2 (0.46) CYP3A4SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL4961185 0.75 SIGMAR1 (0.62) CYP3A4SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL5160673 0.75 NPC1 (0.57) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL25278729 0.74 HTT (0.51) CYP3A4NPC1RAB9AKMT2AMEN1
SCHEMBL24672519 0.74 TDP1 (0.48) CYP3A4TDP1SIGMAR1CA1CA2
SCHEMBL21162702 0.74 DRD2 (0.50) CYP3A4KMT2AMEN1TDP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US disclosed
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US disclosed
WO-2010119984-A1 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE IDO1, TPH1, AHR CYP3A4 503/4885SMN1; SMN2 3554/4885NPC1 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.